Health maintenance organization

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

Retrieved on: 
Wednesday, January 31, 2024

(NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”).

Key Points: 
  • (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”).
  • At the closing, InterCure will cause between 1,755,000 to 1,845,000 shares of the Company to be issued to the Sellers, depending on the share price of the Company at the time of completion.
  • Established in 1988, Leon Pharm is one of the leading private pharmacy chains in Israel, specializing in the customization of pharmaceutical products and cannabis for patients along with providing a high level of professional service.
  • The CEO of InterCure, Alexander Rabinovich, stated: "The acquisition of Leon Pharm is another step towards the implementation of the new medical cannabis reform and the introduction of HMOs.

Reliq Health Technologies, Inc. Announces Expansion of Contract with Large US Health Plan, Expects to Add 50,000 New Patients to iUGO Care

Retrieved on: 
Wednesday, January 10, 2024

The health plan operates Accountable Care Organizations (ACOs) and Health Maintenance Organizations (HMOs) in five States with over 3,000 doctors and more than 1,000,000 patients.

Key Points: 
  • The health plan operates Accountable Care Organizations (ACOs) and Health Maintenance Organizations (HMOs) in five States with over 3,000 doctors and more than 1,000,000 patients.
  • The expansion is expected to add over 50,000 new patients to Reliq’s iUGO Care platform by the end of 2025 at an average revenue of $65 per patient per month.
  • The iUGO Care Remote Patient Monitoring, Chronic Care Management and Behavioral Health Integration solutions Reliq will be providing will enable effective preventative care that allows the ACOs to achieve their cost and quality of care objectives.
  • iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.

TytoCare and St. Luke’s Health System Forge Exclusive Health Care Partnership in Idaho

Retrieved on: 
Wednesday, November 29, 2023

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TytoCare , a virtual care company enabling health plans and providers to deliver accessible, high-quality remote primary care anywhere across the country, and St. Luke’s Health System , the largest health care provider and employer in Idaho, today announced an exclusive partnership that will give its employees and members of St. Luke’s Health Plan access to care from the comfort of home.

Key Points: 
  • NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TytoCare , a virtual care company enabling health plans and providers to deliver accessible, high-quality remote primary care anywhere across the country, and St. Luke’s Health System , the largest health care provider and employer in Idaho, today announced an exclusive partnership that will give its employees and members of St. Luke’s Health Plan access to care from the comfort of home.
  • "We are proud to work with St. Luke’s to bring virtual care to Idaho.”
    As a commitment to enhancing access to care, St. Luke’s Health Plan, a wholly-owned subsidiary of the health system founded in 2022, will offer TytoHome kits to its members beginning in 2024.
  • Luke’s Health Plan was established on the foundation of removing barriers to care and this new partnership with TytoCare is a major step forward in realizing that goal,” said Matt Wolff, President of St. Luke’s Health Plan.
  • “Our partnership with them further drives TytoCare’s mission to provide access to care from anywhere in the world.”

New Illuma Growing-up Infant Formula Now Available throughout China

Retrieved on: 
Thursday, December 21, 2023

The industry responded favorably to the illuma HMO growing-up infant formula as soon as it was made available.

Key Points: 
  • The industry responded favorably to the illuma HMO growing-up infant formula as soon as it was made available.
  • The illuma HMO Growing-Up Infant Formula is intended as a substantially improved nutritional option for preschoolers above 3 years old.
  • With the addition of six crucial HMOs, the company's most recent infant formula product, illuma LUXA, has the highest number of HMOs of any infant formula on the market right now.
  • The introduction of the illuma HMO growing-up infant formula highlights Wyeth Nutrition's "in China, for China" commitment in addition to showcasing the company's overall strength.

New Illuma HMO Growing-up Infant Formula Now Available throughout China

Retrieved on: 
Thursday, December 21, 2023

SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Wyeth Nutrition announced that its first illuma HMO growing-up infant formula added with two human milk oligosaccharides (HMOs) is now available throughout China, which makes Wyeth Nutrition the first multinational company that sells the HMO infant formula in the market just two months after two HMOs were newly authorized as food additives by China's National Health Commission (NHC). Prior to that, the company is also the first foreign company that manufactured HMO infant formula in China, just one month after NHC's approval, at the company's GMP-level factory in Suzhou. Now, Chinese consumers can order the first HMO infant formula added with two HMOs in China via various channels, including the illuma flagship store on Tmall, the Wyeth flagship store on JD.COM, and numerous offline stores across the country.

Key Points: 
  • Prior to that, the company is also the first foreign company that manufactured HMO infant formula in China, just one month after NHC's approval, at the company's GMP-level factory in Suzhou.
  • It took the lead to launch the first illuma HMO growing-up infant formula in November.
  • After the Chinese Government approved the two HMOs, Wyeth illuma reacted quickly by launching the first HMO growing-up infant formula.
  • In 2017, Wyeth Nutrition launched the first illuma HMO product in Hong Kong, to cause quite a stir for HMO formulas.

United States Health Insurance Market Analysis Report 2023: A $1,639 Billion Industry by 2028 from $1,150 Billion in 2022 - Competition, Forecasts and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023

The "United States Health Insurance Market Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Health Insurance Market Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.
  • United States health insurance market is expected to reach a value of $1639.44 billion by 2028, up from $1150.23 billion in 2022, driven by the increasing private health insurance provider and rising medical expenditures during the forecast period.
  • The United States health insurance market has experienced significant growth over the past decade, driven by several factors, such as rising healthcare costs, increasing awareness of health insurance, and a surging population.
  • The United States offers ample opportunities for health insurance companies to expand their offerings beyond traditional health insurance products.

CABIO unveils NeoHMOs™ series at FIE 2023, targeting growing global demand for infant formula

Retrieved on: 
Thursday, November 30, 2023

At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc. as well as the NeoHMOs™ family, including 2'-Fucosyllactose (2'-FL), 3-Fucosyllactose (3'-FL), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LNnT), 3'-sialic lactose (3'-SL), and 6'-sialic lactose (6'-SL).

Key Points: 
  • Over the past 26 years, cumulative visitor count of the prestigious Fi Europe has surpassed 500,000 person/times.
  • This year, CABIO unveiled an exciting new product range, NeoHMOs™, at the FIE 2023.
  • At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc.
  • Our vision is to become a global leader in biotechnology, empowering and enriching lives through nutrition and health.

CABIO unveils NeoHMOs™ series at FIE 2023, targeting growing global demand for infant formula

Retrieved on: 
Thursday, November 30, 2023

At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc. as well as the NeoHMOs™ family, including 2'-Fucosyllactose (2'-FL), 3-Fucosyllactose (3'-FL), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LNnT), 3'-sialic lactose (3'-SL), and 6'-sialic lactose (6'-SL).

Key Points: 
  • Over the past 26 years, cumulative visitor count of the prestigious Fi Europe has surpassed 500,000 person/times.
  • This year, CABIO unveiled an exciting new product range, NeoHMOs™, at the FIE 2023.
  • At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc.
  • Our vision is to become a global leader in biotechnology, empowering and enriching lives through nutrition and health.

Wyeth Becomes the First Multinational Company to Launch an HMO Growing-Up Infant Formula in China

Retrieved on: 
Tuesday, November 14, 2023

SUZHOU, China, Nov. 14, 2023 /PRNewswire/ -- On November 13th, 2023, Wyeth Nutrition announced the launch of its first illuma HMO Growing-up infant formula added with two human milk oligosaccharides (HMOs) in China.

Key Points: 
  • SUZHOU, China, Nov. 14, 2023 /PRNewswire/ -- On November 13th, 2023, Wyeth Nutrition announced the launch of its first illuma HMO Growing-up infant formula added with two human milk oligosaccharides (HMOs) in China.
  • Illuma is now the first international company to introduce an HMO infant formula in China.
  • [2]
    Wyeth Nutrition's long-term dedication and solid research foundation in this area allowed them to become the first foreign company to launch this innovative product in China.
  • The launch of the illuma HMO Growing-up Formula demonstrates Wyeth Nutrition's "in China, for China" commitment in addition to showcasing the company's overall strength.

Wyeth Becomes the First Multinational Company to Launch an HMO Growing-Up Infant Formula in China

Retrieved on: 
Tuesday, November 14, 2023

SUZHOU, China, Nov. 14, 2023 /PRNewswire/ -- On November 13th, 2023, Wyeth Nutrition announced the launch of its first illuma HMO Growing-up infant formula added with two human milk oligosaccharides (HMOs) in China.

Key Points: 
  • SUZHOU, China, Nov. 14, 2023 /PRNewswire/ -- On November 13th, 2023, Wyeth Nutrition announced the launch of its first illuma HMO Growing-up infant formula added with two human milk oligosaccharides (HMOs) in China.
  • Illuma is now the first international company to introduce an HMO infant formula in China.
  • [2]
    Wyeth Nutrition's long-term dedication and solid research foundation in this area allowed them to become the first foreign company to launch this innovative product in China.
  • The launch of the illuma HMO Growing-up Formula demonstrates Wyeth Nutrition's "in China, for China" commitment in addition to showcasing the company's overall strength.